Mizuho analyst Ann Hynes lowered the firm’s price target on Acadia Healthcare (ACHC) to $22 from $32 and keeps a Neutral rating on the shares after the company reported Q2 results that missed consensus estimates when excluding the incremental impact of direct provider payments in the quarter. The firm, which reduced its 2025-2027 adjusted EBITDA estimates, is staying on the sidelines, citing “execution missteps” along with uncertainty on the impact of ongoing Medicaid Redeterminations and the One Big Beautiful Bill Act.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare price target lowered to $28 from $43 at RBC Capital
- Acadia Healthcare price target lowered to $25 from $44 at TD Cowen
- Acadia Healthcare: Buy Rating Amid Growth Potential and Operational Challenges
- Acadia Healthcare: Strategic Adjustments and Growth Prospects Justify Buy Rating Amid Medicaid Challenges
- Acadia Healthcare price target lowered to $20 from $28 at Barclays